title: Exenatide.
authors.affiliation: Charles R. Drew University, Los Angeles, California 90059, USA. madavids@cdrewu.edu
authors.forename: Mayer B
authors.initials: MB
authors.lastname: Davidson
authors.forename: Guy
authors.initials: G
authors.lastname: Bate
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D004334:Drug Administration Schedule; D017277:Drug Approval; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006801:Humans; D040541:Marketing / Q000191:economics / Q000379:methods; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D014688:Venoms / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D010455:Peptides; D014688:Venoms; D000077270:Exenatide